Head-to-head
GHRP-2 vs GHRP-6
Side by side from the same data: half-life, evidence tier, research amounts, common schedule, and every decay curve on one chart.
How they differ
A plain-language read of what actually sets them apart. Reference only, not medical advice.
Two of the earliest growth-hormone release peptides, working the same switch. GHRP-2 is the stronger trigger and is used in Japan as a single-dose gland test; GHRP-6 brings on more hunger. Both clear in about twenty minutes, so both act as short bursts rather than building up.
Side by side
Every figure is drawn from this site's own compound data — the same numbers on each compound's page.
| Measure | GHRP-2 | GHRP-6 |
|---|---|---|
| Category | Growth hormone axis | Growth hormone axis |
| Evidence | A · Tested in people | B · Some human use |
| Route | Intravenous | Subcutaneous |
| Half-life | 0.4 h | 0.3 h |
| Typical vial | 5 / 10 mg | 5 / 10 mg |
| Research amount | 100–100 mcg | 100–200 mcg |
| Common schedule | Every day | Twice a day |
| Cycle / break | — | — |
| Studied for | Growth-hormone release | Growth-hormone release |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Every compound on one chart — something the single-compound pages cannot show.
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.